Login to Your Account



Reverse Vaccine Strikes Blow Against Type I Diabetes

By Catherine Shaffer
Staff Writer

Wednesday, June 26, 2013
newco_news_resized.jpg

Tolerion Inc. reported Phase II results showing promising disease-modifying activity of its lead product TOL-3021 against Type I diabetes.

The product preserved pancreatic beta-cell function while reducing T-cell activity in patients with the disease, as published in Science Translational Medicine.

The product is a "reverse" vaccine designed to selectively suppress specific elements of the immune system that are inappropriately activated in Type I diabetes.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription